



ASO VISUAL ABSTRACT


ASO Visual Abstract: Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer—Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries

Lee G. Wilke, MD¹, Toan Thien Nguyen, MD², Qiuyu Yang³, Bret M. Hanlon, PhD³, Kathryn A. Wagner, MD⁴, Pamela Strickland, MD⁵, Eric Brown, MD⁶, Jill R. Dietz, MD, MHCM⁷, and Judy C. Boughey, MD⁸

¹Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI; ²Surgical Oncology, Lakeland Regional Health Physician Group, Lakeland, FL; ³UW Department of Surgery, Madison, WI; ⁴Texas Breast Specialists, San Antonio, TX; ⁵Montgomery Baptist Breast Surgery Clinic, Montgomery, AL; ⁶Comprehensive Breast Care, Troy, MI; ⁷Growth and Strategy Breast Program, Allegheny Health Network Cancer Institute, Pittsburgh, PA; ⁸Division of Breast and Melanoma Surgical Oncology Department of Surgery, Mayo Clinic, Rochester, MN

The American Society of Breast Surgeons COVID-19 specific patient registry provided a platform for evaluating oncologic treatment changes during the first year of the

pandemic (<https://doi.org/10.1245/s10434-021-10497-x>). The primary alteration in patient care was an increased use of neoadjuvant endocrine therapy.



DISCLOSURES L. G. Wilke: Founder/Minority Stock Owner Elucent Medical; Institutional support for clinical trial/Perimeter Medical—unrelated to the manuscript. Judy C. Boughey MD, Professor of Surgery, Mayo Clinic: Funding from Eli Lilly for clinical trial—paid to institution—unrelated to this manuscript.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.